Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03639766 · ClinicalTrials.gov registry record · Phase 4
The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon
A Phase 4 study, sponsored by University of Central Florida.
- Terminated
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT03639766 is a Phase 4 study that was terminated before completion, run by University of Central Florida. The registered enrollment target is 3 participants.
The verdict
NCT03639766, a Phase 4 study, was terminated before completion, sponsored by University of Central Florida.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study aims to investigate the effect of abobotulinum toxin A on the symptoms of Raynaud's phenomenon.
Interventions
- DRUG AbobotulinumtoxinA
- OTHER Saline solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-08-31 |
| Est. Completion | 2020-01-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03639766
The ClinicalTrials.gov registry entry for NCT03639766 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Central Florida, which has 91 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AbobotulinumtoxinA is the first listed.
NCT03639766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03639766 about?
NCT03639766 is a clinical study titled "The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon". This study aims to investigate the effect of abobotulinum toxin A on the symptoms of Raynaud's phenomenon.
What is the current status of trial NCT03639766?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2018-08-31. Estimated completion is 2020-01-31.
What interventions are being tested in trial NCT03639766?
The interventions under investigation include: AbobotulinumtoxinA (DRUG), Saline solution (OTHER).
Who is sponsoring clinical trial NCT03639766?
This trial is sponsored by University of Central Florida, which has 91 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.